

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

Petitioner,

v.

NOVARTIS AG,

Patent Owner.

Case IPR2016-00084

Patent No. 5,665,772

**EXPERT DECLARATION
OF WILLIAM R. ROUSH, PH.D.**

TABLE OF CONTENTS

I.	QUALIFICATIONS	1
II.	ASSIGNMENT.....	8
III.	SUMMARY OF OPINIONS.....	9
IV.	LEGAL PRINCIPLES.....	12
	A. Priority	12
	B. Obviousness.....	13
	C. Person Of Ordinary Skill In The Art.....	17
V.	THE '772 PATENT	18
VI.	GROUND 1: CLAIMS 1-3 AND 10 OF THE '772 PATENT WOULD NOT HAVE BEEN OBVIOUS TO A PERSON OF ORDINARY SKILL IN THE ART IN VIEW OF MORRIS, LEMKE, YALKOWSKY, VAN DUYNE AND ROSSMANN.....	21
	A. Dr. Jorgensen's Arguments About The C40 Groups A POSA Would Consider Are Unsupported.....	23
	1. Prior Art Rapamycin Derivatives Were Not Limited To Those With Small C40 Groups.....	24
	2. One Of Ordinary Skill In The Art Would Have Considered Substituents Containing Ester, Amide, Carboxylic Acid And/Or Phenol Groups.....	42
	3. The Structure Of Rapamycin Bound To FKBP-12 Would Not Have Led One Of Ordinary Skill To Consider Only Dr. Jorgensen's "Small" Substituents	52
	4. Dr. Jorgensen Ignores Substituents Other Than Those Attached To C40 By An Oxygen Atom.....	58
	5. One Of Ordinary Skill Would Not Have Had A Reasonable Expectation Of Success	64

..

B.	Dr. Jorgensen Does Not Compare The Properties Of Rapamycin With Other Known Immunosuppressants Or Explain Why A Person Of Ordinary Skill Knowing Those Comparative Properties Would Have Nevertheless Selected Rapamycin	90
1.	Dr. Jorgensen’s Identification Of Rapamycin As A Lead Compound Based On Morris	91
2.	Dr. Jorgensen Did Not Explain Why A Person Of Ordinary Skill Knowing The Properties Of Other Immunosuppressants Would Have Nevertheless Selected Rapamycin.....	97
3.	One Of Ordinary Skill In The Art Would Not Have Selected Rapamycin As A Lead Compound Based On Van Duyne	103
4.	One Of Ordinary Skill In The Art Would Not Have Selected Rapamycin As A Lead Compound Based On Stella, Hughes, And Schiehser.....	105
C.	Dr. Jorgensen’s Selection Of The C40 Position	107
1.	Dr. Jorgensen’s Discussion Of Rapamycin’s Binding And Effector Domains Based On Schreiber And Van Duyne Is Incorrect.....	108
2.	Dr. Jorgensen Improperly Relies On Van Duyne’s Three-Dimensional Coordinates Of Rapamycin Bound To FKBP-12	113
3.	Dr. Jorgensen Ignores What Positions Were Being Modified In The Prior Art As A Whole.....	113
D.	Objective Indicia Of Non-Obviousness Support My Conclusion That Everolimus Would Not Have Been Obvious.....	123
1.	Novartis’s Zortress® And Afinitor® Products Are Covered By Claims 1-3 And/Or 8-10 Of The ’772 Patent.....	124

...

2.	There Was A Long-Felt Need For A Safe And Effective Immunosuppressant Treatment	126
3.	Failure Of Others To Develop New Immunosuppressants To Prevent Transplant Rejection	127
4.	Unexpected Results.....	128
5.	Conclusion	130
VII.	GROUND 2: CLAIMS 8 AND 9 WOULD NOT HAVE BEEN OBVIOUS TO A PERSON OF ORDINARY SKILL IN LIGHT OF MORRIS, VAN DUYNE, ROSSMAN, YALKOWSKY, LEMKE AND HUGHES.....	131

I, William R. Roush, Ph.D., declare as follows:

I. QUALIFICATIONS

1. I am Professor of Chemistry and Executive Director of Medicinal Chemistry of the Scripps Research Institute in Jupiter, Florida (“Scripps Florida”). A copy of my curriculum vitae is included as Exhibit 2094. My educational background and my professional experience are summarized below.

2. I obtained a Bachelor of Science degree in Chemistry from the University of California, Los Angeles in 1974, graduating *summa cum laude*. I obtained my Ph.D. in Chemistry from Harvard University in 1977. My Ph.D. thesis concerned the synthesis of a natural product known as dendrobine.

3. After a year of post-doctoral work at Harvard (1977-78), I joined the faculty at the Massachusetts Institute of Technology (MIT) as an Assistant Professor of Chemistry. I taught chemistry courses and performed research at MIT from 1978 to 1987. My research interests included the total synthesis of natural products and the development of new synthetic methods.

4. In 1987, I moved to Indiana University, where I ultimately became Distinguished Professor of Chemistry. At Indiana University, I initiated a research program on the design and synthesis of inhibitors of cysteine proteases. In 1997, I was appointed the Warner-Lambert/Parke-Davis Professor of Chemistry at the University of Michigan. This is an endowed chair established by a gift from

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.